X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CADILA HEALTHCARE - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CADILA HEALTHCARE IPCA LABS/
CADILA HEALTHCARE
 
P/E (TTM) x 27.7 35.2 78.7% View Chart
P/BV x 2.1 9.1 23.4% View Chart
Dividend Yield % 0.2 0.7 35.9%  

Financials

 IPCA LABS   CADILA HEALTHCARE
EQUITY SHARE DATA
    IPCA LABS
Mar-17
CADILA HEALTHCARE
Mar-16
IPCA LABS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs643454 141.5%   
Low Rs503305 165.1%   
Sales per share (Unadj.) Rs254.496.1 264.7%  
Earnings per share (Unadj.) Rs16.114.9 108.0%  
Cash flow per share (Unadj.) Rs29.817.8 167.0%  
Dividends per share (Unadj.) Rs1.003.20 31.3%  
Dividend yield (eoy) %0.20.8 20.7%  
Book value per share (Unadj.) Rs194.652.3 372.2%  
Shares outstanding (eoy) m126.201,023.74 12.3%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x2.33.9 57.0%   
Avg P/E ratio x35.725.5 139.7%  
P/CF ratio (eoy) x19.221.3 90.4%  
Price / Book Value ratio x2.97.3 40.6%  
Dividend payout %6.221.5 28.9%   
Avg Mkt Cap Rs m72,300388,458 18.6%   
No. of employees `00013.315.4 86.2%   
Total wages/salary Rs m6,96013,317 52.3%   
Avg. sales/employee Rs Th2,413.56,371.1 37.9%   
Avg. wages/employee Rs Th523.2862.4 60.7%   
Avg. net profit/employee Rs Th152.4986.1 15.5%   
INCOME DATA
Net Sales Rs m32,10698,376 32.6%  
Other income Rs m226941 24.0%   
Total revenues Rs m32,33299,317 32.6%   
Gross profit Rs m4,44823,829 18.7%  
Depreciation Rs m1,7303,022 57.2%   
Interest Rs m241486 49.5%   
Profit before tax Rs m2,70321,262 12.7%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m6755,716 11.8%   
Profit after tax Rs m2,02815,226 13.3%  
Gross profit margin %13.924.2 57.2%  
Effective tax rate %25.026.9 92.9%   
Net profit margin %6.315.5 40.8%  
BALANCE SHEET DATA
Current assets Rs m17,34044,376 39.1%   
Current liabilities Rs m9,55934,071 28.1%   
Net working cap to sales %24.210.5 231.3%  
Current ratio x1.81.3 139.3%  
Inventory Days Days10054 186.3%  
Debtors Days Days5762 91.2%  
Net fixed assets Rs m20,77947,896 43.4%   
Share capital Rs m2521,024 24.6%   
"Free" reserves Rs m24,49948,746 50.3%   
Net worth Rs m24,55353,519 45.9%   
Long term debt Rs m3,5178,964 39.2%   
Total assets Rs m39,595100,163 39.5%  
Interest coverage x12.244.7 27.3%   
Debt to equity ratio x0.10.2 85.5%  
Sales to assets ratio x0.81.0 82.6%   
Return on assets %5.715.7 36.5%  
Return on equity %8.328.4 29.0%  
Return on capital %10.534.3 30.6%  
Exports to sales %48.645.3 107.4%   
Imports to sales %14.25.9 239.9%   
Exports (fob) Rs m15,61744,537 35.1%   
Imports (cif) Rs m4,5715,838 78.3%   
Fx inflow Rs m15,61744,881 34.8%   
Fx outflow Rs m5,8289,069 64.3%   
Net fx Rs m9,79035,812 27.3%   
CASH FLOW
From Operations Rs m2,76419,938 13.9%  
From Investments Rs m-1,432-9,039 15.8%  
From Financial Activity Rs m-1,591-9,527 16.7%  
Net Cashflow Rs m-2591,372 -18.9%  

Share Holding

Indian Promoters % 45.9 74.8 61.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.3 137.3%  
FIIs % 25.3 5.9 428.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 11.0 158.2%  
Shareholders   36,892 44,069 83.7%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 18, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS